Page 68 - 2021_07-Haematologica-web

S. Chiaretti et al.
front-line treatment of elderly patients with
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer. 2007;109(10):2068-2076.
9. Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long- term outcome of adult patients with Philadelphia chromosome- positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28(22):3644-3652.
10. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multi-center LALA-94 trial. Blood. 2002;100(7):2357-2366.
11. Laport GG, Alvarnas JC, Palmer JM. Long- term remission of Philadelphia chromo- some-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the frac- tionated total body irradiation-etoposide regimen. Blood. 2008; 112(3):903-909.
12. Fielding AK, Rowe JM, Richards SM. Prospective outcome data on 267 unselect- ed adult patients with Philadelphia chro- mosome–positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009; 113(19):4489-4496.
13. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood. 2006;108(5):1469-1477.
14. de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Imatinib combined with induction or con- solidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007;109 (4):1408-1413.
15.Ribera JM, Oriol A, Gonzalez M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell trans- plantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2010;95(1):87-95.
16. Foà R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521-6528.
17. Chiaretti S, Vitale A, Vignetti M, et al. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL0904 study. Haematologica. 2016;101(12):1544-1552.
18.Fielding AK, Rowe JM, Buck G, et al.
UKALLXII/ECOG2993: addition of ima- tinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123(6):843-850.
19. Ribera JM, García O, Montesinos P, et al. Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. Br J Haematol. 2012;159 (1):78-81.
20. Chalandon Y, Thomas X, Hayette S, et al; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblas- tic leukemia. Blood. 2015;125(24):3711- 3719.
21. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17(12): 2318-2357.
22. Elia L, Mancini M, Moleti L, et al. A multi- plex reverse transcriptase polymerase chain reaction strategy for the diagnostic molecu- lar screening of chimeric genes: a clinical evaluation on 170 patients with acute lym- phoblastic leukemia. Haematologica. 2003;88(3):275-279.
23. Fedullo AL, Messina M, Elia L, et al. Prognostic implications of additional genom- ic lesions in adult Philadelphia chromosome- positive acute lymphoblastic leukemia. Haematologica. 2019;104(2):312-318.
24. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – A metadata- driven methodology and workflow process for providing transla- tional research informatics support. J Biomed Inform. 2009;42(2):377-381.
25. Harris PA, Taylor R, Minor BL, et al. The REDCap Consortium: building an interna- tional community of software partners. J Biomed Inform.2019;95:103208.
26.Pfeifer H, Raum K, Markovic S, et al. Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation. Blood. 2018;131 (13):1464-1475.
27. Ravandi F, O'Brien SM, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121(23):4158-4164.
28. Daver N, Thomas D, Ravandi F, et al. Final report of a phase II study of imatinib mesy- late with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015;100(5):653-661.
29. Lim SN, Joo YD, Lee KH, et al. Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diag- nosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2015;90(11):1013-1020.
30.Hatta Y, Mizuta S, Matsuo K, et al. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ ALL. Ann Hematol. 2018;97(9):1535-1545.
31. Foà R, Bassan R, Vitale A, et al. Dasatinib- blinatumomab for Ph-positive acute lym- phoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613-1623.
32. Rousselot P, Coudé MM, Gokbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chro- mosome-positive ALL. Blood. 2016;128(6): 774-782.
33. Ravandi F, Othus M, O'Brien SM, et al. US Intergroup study of chemotherapy plus dasatinib and allogeneic stem cell trans- plant in Philadelphia chromosome positive ALL. Blood Adv. 2016;1(3):250-259.
34. Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126(6):746-756.
35. Short N, Kantarjian HM, Ravandi F, et al. Long-term safety and efficacy of Hyper- CVAD plus ponatinib as frontline therapy for adults with Philadelphia chromosome- positive acute lymphoblastic leukemia. Blood. 2019;134(Suppl. 1):S283.
36. Chang J, Douer D, Aldoss I, et al. Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia. Cancer Med. 2019;8(6):2832- 2839.
37. Candoni A, Rambaldi A, Fanin R, et al. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of tyro- sine kinase inhibitors: a registry-based study of the Italian Blood and Marrow Transplantation Society (GITMO). Biol Blood Marrow Transplant. 2019;25(12): 2388-2397.
38.Jabbour E, Short NJ, Ravandi F, et al. Combination of hyper-CVAD with pona- tinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term fol- low-up of a single-centre, phase 2 study. Lancet Haematol. 2018;5(12):e618-e627. Martinelli G, Piciocchi A, Papayannidis C, et al. First report of the GIMEMA LAL1811 phase II prospective study of the combina- tion of steroids with ponatinib as frontline therapy of elderly or unfit patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2017;130 (Suppl.1):S99.
39.
1838
haematologica | 2021; 106(7)